RET inhibitors are an exciting development for non-small cell lung cancer (NSCLC) and thyroid cancers.
- Discover how RET inhibitors work and review summaries of their efficacy and safety
- Our leading experts Dr Alexander Drilon and Professor Lori Wirth highlight the importance of testing for RET gene alterations
- Hear from Professor Fernando Lopez-Rios, an expert pathologist, on improving and interpreting molecular test outcomes
Professor Fernando Lopez-Rios, a professor of Pathology and Molecular Pathology at Universidad CEU San Pablo in Madrid, Spain, highlights why it is important to learn about testing for rearranged during transfection (RET) gene alterations in patients with non-small cell lung cancer (NSCLC) and thyroid cancer.
The RET inhibitors selpercatinib and pralsetinib present novel treatment opportunities for NSCLC and thyroid cancer patients harbouring alterations in the proto-oncogene RET
Throughout the Learning Zone, leading experts in the field of NSCLC (Dr Alexander Drilon) and thyroid cancer (Professor Lori Wirth) discuss the impact of RET gene alterations on the treatment options available for their patients. Professor Lopez-Rios shares insights into molecular testing techniques used to identify RET alterations, tips for successful test outcomes, and how to interpret results.
Learn how to identify patients who may be eligible for RET inhibition and find out how to monitor and manage possible side effects.
Mode of action, indications, efficacy and safety of RET inhibitors
Stratifying patients with NSCLC and thyroid cancers
Molecular testing techniques used to identify RET alterations
Take a deep dive into our publication digests to learn more about RET inhibitors and their impact on the treatment and management of non-small cell lung cancer (NSCLC) and thyroid cancers
Meet the experts
Dr Alexander Drilon
Dr Alexander Drilon is the Chief of the Early Drug Development Service and an Associate Attending Physician of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center in New York City, USA.
Professor Lori Wirth
Professor Lori Wirth is Associate Professor of Medicine at Harvard Medical School and Medical Director of the Center for Head and Neck Cancers at Massachusetts General Hospital, Boston, USA.
Professor Fernando Lopez-Rios
Professor Fernando Lopez-Rios is full professor of Pathology and Molecular Pathology at the Department of Medical Sciences, San Pablo CEU University, Madrid, Spain.
Developed by EPG Health for Medthority. This content has been developed independently of the sponsor Eli Lilly, who have had no editorial input into the content. EPG Health received unrestricted educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.